BME100 s2015:Group11 12pmL2: Difference between revisions
Miranda Kaml (talk | contribs) |
|||
(38 intermediate revisions by 3 users not shown) | |||
Line 13: | Line 13: | ||
{| style="wikitable" width="700px" | {| style="wikitable" width="700px" | ||
|- valign="top" | |- valign="top" | ||
| [[Image: | | [[Image:FramPic.jpg|100px|thumb|Framarz Alam]] | ||
| [[Image: | | [[Image:Miranda.JPG|100px|thumb|Name: Miranda Kaml]] | ||
| [[Image: | | [[Image:JoePic.jpg|100px|thumb|Name: Joe Florio]] | ||
| [[Image:BME103student.jpg|100px|thumb|Name: Your name]] | | [[Image:BME103student.jpg|100px|thumb|Name: Your name]] | ||
| [[Image:BME103student.jpg|100px|thumb|Name: Your name]] | | [[Image:BME103student.jpg|100px|thumb|Name: Your name]] | ||
Line 29: | Line 29: | ||
Average Inflammotin Concentration in Human Groups: | Average Inflammotin Concentration in Human Groups: | ||
0mg LPS | {| {{table}} | ||
|- | |||
|0mg LPS||5mg LPS||10mg LPS||15mg LPS | |||
|- | |||
|3.834 pg/ml||8.932 pg/ml||61.622 pg/ml||657.941 pg/ml | |||
|} | |||
'''Experiment 2'''<br> | '''Experiment 2'''<br> | ||
Line 41: | Line 40: | ||
Average Inflammotin Concentration in Rat Groups: | Average Inflammotin Concentration in Rat Groups: | ||
0mg LPS | {| {{table}} | ||
|- | |||
|0mg LPS||10mg LPS | |||
|- | |||
|10.516 pg/ml||11.112 pg/ml | |||
|} | |||
<br><br> | <br><br> | ||
Line 51: | Line 53: | ||
'''Experiment 1''' <br> | '''Experiment 1''' <br> | ||
[[Image:Labgroup2Human.png|thumb|frame|left|Human Study]] | [[Image:Labgroup2Human.png|thumb|frame|left|Human Study]]<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br> | ||
'''Experiment 2''' <br> | '''Experiment 2''' <br> | ||
Line 58: | Line 60: | ||
<br><br> | <br><br><br><br><br><br><br><br><br><br><br><br><br><br> | ||
==Analysis== | ==Analysis== | ||
Line 64: | Line 66: | ||
'''Experiment 1''' <br> | '''Experiment 1''' <br> | ||
Variance in Human Groups | |||
{| {{table}} | |||
|- | |||
|Groups||Count||Sum||Average||Variance | |||
|- | |||
|Column 1||10||38.34||3.834||2.31956 | |||
|- | |||
|Column 2||10||89.32||8.932||2.54062 | |||
|- | |||
|Column 3||10||616.22||61.622||906.65388 | |||
|- | |||
|Column 4||10||6579.41||657.941||45344.71112 | |||
|}<br> | |||
Single Factor ANOVA for Human Groups | |||
{| {{table}} | |||
|- | |||
|Source of Variation||SS||df||MS||F||P-Value||F crit | |||
|- | |||
|Between Groups||3027016.695||3||1009005.565||97.254||1.401E-16||2.866 | |||
|- | |||
|Within Groups||416306.027||36||11564.056|||||| | |||
|- | |||
|Total||3443322.721||39|||||||| | |||
|}<br> | |||
Bonferroni Correction for ANOVA in Human Groups | |||
{| {{table}} | |||
|- | |||
|Post-hoc test||t-test value||p-value||Significant? | |||
|- | |||
|0-5mg||8.59631E-07||1.43272E-07||Yes | |||
|- | |||
|0-10mg||9.94377E-06||1.6573E-06||Yes | |||
|- | |||
|0-15mg||1.39436E-08||2.32394E-09||Yes | |||
|- | |||
|5-10mg||3.01859E-05||5.03099E-06||Yes | |||
|- | |||
|5-15mg||1.57101E-08||2.61835E-09||Yes | |||
|- | |||
|10-15mg||6.4824E-08||1.0804E-08||Yes | |||
|}<br> | |||
The ANOVA test is run on the human group due to the fact that there are four different doses of LPS, and therefore four different groups between which the differences are being investigated. | |||
'''Experiment 2''' <br> | '''Experiment 2''' <br> | ||
T-Test Value for Rat Group: 0.867403497<br><br> | |||
P-Value for Rat Group: 0.545129<br><br> | |||
Significance?<br> | |||
No. 0.545129>0.05<br><br> | |||
The T-test is run on the rat group since differences are only being examined between two groups. | |||
<br><br> | <br><br> | ||
==Summary/Discussion== | ==Summary/Discussion== | ||
According to the p-value for experiment 1, there is a significant difference among the four doses of LPS in humans because the variance in error does not overlap in each dose on the bar graph. In the Bonferroni correction the comparison between all groups showed significance when comparing the t-test values to the corrected p-value because the t-values were less than the p-values. This means the dose of LPS present in the elderly, does make a difference in the amount of inflammotin in elderly. In experiment 2, there was no significant difference between the doses of LPS in the rats because the p-value obtained from the t-test was greater than the acceptable p-value of 0.05. This means the doses of LPS does not make a significant difference in the amount of inflammotin produced in rats. The link from the two experiments is that the different doses of LPS does make a difference in the humans’ production of inflammotin, as recorded among several groups, while LPS contributes no effect to the rat’s ability to produce inflammotin. |
Latest revision as of 18:38, 3 February 2015
BME 100 Spring 2015 | Home People Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3 Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6 Course Logistics For Instructors Photos Wiki Editing Help | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
OUR TEAMLAB 2 WRITE-UPDescriptive StatisticsExperiment 1 Average Inflammotin Concentration in Human Groups:
Experiment 2 Average Inflammotin Concentration in Rat Groups:
ResultsExperiment 1 Experiment 2
AnalysisExperiment 1 Variance in Human Groups
Single Factor ANOVA for Human Groups
Bonferroni Correction for ANOVA in Human Groups
The ANOVA test is run on the human group due to the fact that there are four different doses of LPS, and therefore four different groups between which the differences are being investigated. Experiment 2 T-Test Value for Rat Group: 0.867403497 P-Value for Rat Group: 0.545129 Significance? No. 0.545129>0.05 The T-test is run on the rat group since differences are only being examined between two groups.
Summary/DiscussionAccording to the p-value for experiment 1, there is a significant difference among the four doses of LPS in humans because the variance in error does not overlap in each dose on the bar graph. In the Bonferroni correction the comparison between all groups showed significance when comparing the t-test values to the corrected p-value because the t-values were less than the p-values. This means the dose of LPS present in the elderly, does make a difference in the amount of inflammotin in elderly. In experiment 2, there was no significant difference between the doses of LPS in the rats because the p-value obtained from the t-test was greater than the acceptable p-value of 0.05. This means the doses of LPS does not make a significant difference in the amount of inflammotin produced in rats. The link from the two experiments is that the different doses of LPS does make a difference in the humans’ production of inflammotin, as recorded among several groups, while LPS contributes no effect to the rat’s ability to produce inflammotin. |